Skip to content
We Ship Nationwide·Ships Free Over $125·Lab-Tested Products·Ships Next Business Day·Plain Unmarked Packaging· We Ship Nationwide·Ships Free Over $125·Lab-Tested Products·Ships Next Business Day·Plain Unmarked Packaging·
Kratom619
⚖️ Scheduled August 27, 2026

SR-17018: what changed

Sold as SR-17, Simple Reset, O.R. Reset and Reset Mode, and marketed as a tolerance reset. As of August 27, 2026 it's a Schedule I controlled substance under a temporary DEA order. Here's the compound, the scheduling, and what the reset claim actually rests on — no product pitch attached.

What it isA synthetic mu-opioid receptor agonist developed at Scripps Research Institute. Not a kratom alkaloid, not a botanical, not a supplement.
Sold asSR-17, Simple Reset, O.R. Reset, Reset Mode — and as “research-grade” powder and solution.
The marketing claimA “tolerance reset” — lower tolerance, return to baseline, step down from heavier daily use.
Human evidenceNo completed human clinical trials. The published human information is self-report, not trial data.
Federal statusSchedule I. Temporary scheduling order effective August 27, 2026, in force through August 27, 2028.

Regulatory status, published pharmacology and label facts only — no health claims, no dosing guidance, ever.

What the scheduling says

The DEA published its notice of intent on July 1, 2026, listing the compound under its chemical name — 5,6-dichloro desmethylchlorphine — which is part of why so few retailers noticed: the paperwork doesn’t say “SR-17018” on the front. The temporary scheduling order took effect August 27, 2026 and runs through August 27, 2028.

It’s worth knowing that this one is disputed. Students for Sensible Drug Policy and the Rights & Reason Project filed an administrative request in late July to pull the compound from the emergency order, arguing there was no evidence it posed the “imminent hazard to public safety” that emergency scheduling requires — and pointing out that SR-17018 came out of NIH-funded research into safer pain medicine. The DEA proceeded anyway. That challenge doesn’t change the current legal status; it just means this may not be the end of the story.

Where the “tolerance reset” idea came from

SR-17018 was built at Scripps to test a real scientific idea: that a mu-opioid agonist biased toward G-protein signalling might separate pain relief from the things that make opioids dangerous — respiratory depression, tolerance, dependence. In rodent studies it looked like it might, and it appeared to blunt tolerance rather than build it. That result is the entire basis of every “reset” product on the market.

Two things the marketing leaves out. There are no completed human clinical trials — not for tolerance, not for withdrawal, not for safety. Every human account of this compound is somebody’s self-report. And the headline safety finding has a hole in it: the original work showing no respiratory depression dosed mice by injection, while oral dosing — the only route anyone actually uses — does produce significant respiratory depression in mice. The specific numbers vendors quote, like roughly half your tolerance in two to three days and baseline in a week, are marketing copy. They aren’t trial results, because there are no trials.

The names it sold under

One compound, a lot of front labels: Simple Reset (also branded SR-17), O.R. Reset, Reset Mode, and a handful of sites selling it as “research-grade” powder or solution. The scheduling is about the molecule, so it reaches all of them equally, whatever the packaging says about being kratom-free or lab-screened.

If this feels familiar, it should. Concentrated 7-OH was federally scheduled three weeks earlier — the same thing happened to Numbz, 7-OHMZ and the Dozo combo tabs — and the cat’s-claw tablet wave that followed is already drawing poison-control alerts and a state AG investigation. Three compounds, one pattern: a novel molecule arrives wearing wellness language, sells hard for a few months, and gets scheduled. Whatever replaces SR-17018 will follow it.

SR-17018, answered

Is SR-17018 legal?
No. The DEA placed SR-17018 — listed under its chemical name, 5,6-dichloro desmethylchlorphine — into Schedule I under a temporary scheduling order that took effect August 27, 2026 and runs through August 27, 2028. Schedule I is the same tier as the August 2026 action on concentrated 7-OH. This is a federal restriction, not a state rule and not a stock issue.
Is SR-17018 kratom?
No. Kratom alkaloids come from the leaf of Mitragyna speciosa. SR-17018 is a synthetic compound designed in a lab at Scripps Research Institute as part of opioid receptor research — it isn’t found in the plant and isn’t derived from it. Products built on it that describe themselves as kratom-free are telling the truth about that specific point; it doesn’t make them legal.
Does SR-17018 actually reset tolerance?
Nobody knows, and that’s the honest answer. The idea comes from rodent work out of the Scripps lab that developed it, where G-protein biased signalling appeared to produce less tolerance than conventional opioids. There are no completed human clinical trials. The specific timelines you’ll see quoted — around 50% in a few days, baseline in about a week — come from vendor material, not from a trial. We make no claims about what it does.
Wasn’t it supposed to be safer than opioids?
That was the research question, and the result has not held up as cleanly as the marketing suggests. The original finding that it avoids respiratory depression came from work dosing mice by injection. When mice are dosed orally — the route people actually use — significant respiratory depression does occur. That single difference undercuts the safety claim the whole category was built on.
Why is it still for sale on some sites?
The same reason Numbz listings stayed up after August 5: distributors move remaining stock and retail listings lag the law. The temporary scheduling order took effect August 27, 2026, and applies nationwide regardless of what a product page says. A listing being live is not a statement about its legality.
Do you sell SR-17018, or anything like it?
No — and we don’t sell an alternative to it either. We sell kratom and mitragynine products. Nothing on our menu lowers tolerance, and we’re not going to point someone who came here trying to use less toward a shelf of what they’re trying to use less of. If that’s why you’re reading this, the helpline at the bottom of the page is a better answer than anything we stock.

We don't sell this, or a substitute for it.

This page exists because the honest answer was hard to find, not to move you onto something else. If you've got a question about what's changed, a real person answers.

💬 Text us a question — (619) 413-7464

If you’re trying to cut down

We sell kratom. We’re not the right people to advise anyone on stepping away from it, and we won’t pretend otherwise. The SAMHSA National Helpline is free, confidential and staffed 24/7: 1-800-662-4357.